Bigelow Investment Advisors’s GSK GSK Stock Holding History

Bigelow Investment Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,955	Closed	-$212K	–	155
2024 Q1	$212K	Buy	+4,955	New	+$204K	0.1%	150
2023 Q3	–	Sell	-7,830	Closed	-$279K	–	148
2023 Q2	$279K	Hold	7,830	–	–	0.15%	129
2023 Q1	$279K	Hold	7,830	–	–	0.16%	127
2022 Q4	$275K	Sell	7,830 -1,150	-13%	-$38.3K	0.16%	125
2022 Q3	$264K	Hold	8,980	–	–	0.16%	123
2022 Q2	$489K	Hold	8,980	–	–	0.27%	99
2022 Q1	$489K	Hold	8,980	–	–	0.23%	97
2021 Q4	$495K	Buy	+8,980	New	+$467K	0.23%	95
2019 Q2	–	Sell	-4,080	Closed	-$213K	–	152
2019 Q1	$213K	Buy	+4,080	New	+$204K	0.15%	145
2018 Q4	–	Sell	-4,120	Closed	-$207K	–	151
2018 Q3	$207K	Hold	4,120	–	–	0.14%	151
2018 Q2	$208K	Buy	+4,120	New	+$208K	0.14%	146

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Bigelow Investment Advisors's GSK Position: Q2 2024 in Review

Bigelow Investment Advisors sold out of GSK (GSK) in Q2 2024, closing a stake of 4,955 shares — an estimated $212K sold.

Bigelow Investment Advisors first reported a position in GSK in Q2 2018 and held it in 11 quarters. The position peaked at $495K in Q4 2021. 885 funds tracked by Wall St. Rank hold GSK as of Q2 2024.

Bigelow Investment Advisors reported no remaining GSK position as of Q2 2024 after selling out during the quarter.
Bigelow Investment Advisors sold 4,955 GSK shares in Q2 2024, an estimated $212K.
Bigelow Investment Advisors first reported a position in GSK in Q2 2018 and held it in 11 quarters.
Bigelow Investment Advisors's GSK position peaked at $495K in Q4 2021.
885 funds tracked by Wall St. Rank held GSK as of Q2 2024.

Based on Bigelow Investment Advisors's 13F filing for Q2 2024, filed 8 Aug 2024.